Macular Degeneration Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Macular Degeneration stocks.

Recent Signals

Date Stock Signal Type
2021-07-27 ADVM Calm After Storm Range Contraction
2021-07-27 ADVM Lower Bollinger Band Walk Weakness
2021-07-27 ADVM Boomer Sell Setup Bearish Swing Setup
2021-07-27 ADVM New 52 Week Closing Low Bearish
2021-07-27 ALIM Bollinger Band Squeeze Range Contraction
2021-07-27 APLS 20 DMA Support Bullish
2021-07-27 APLS Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-07-27 BNTC Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-07-27 BNTC 20 DMA Resistance Bearish
2021-07-27 BNTC 200 DMA Resistance Bearish
2021-07-27 CLSD Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-07-27 CLSD Bollinger Band Squeeze Range Contraction
2021-07-27 CLSD 1,2,3 Pullback Bullish Bullish Swing Setup
2021-07-27 DFFN New 52 Week Closing Low Bearish
2021-07-27 EYPT Crossed Above 20 DMA Bullish
2021-07-27 GILD Cup with Handle Other
2021-07-27 GILD Bollinger Band Squeeze Range Contraction
2021-07-27 GILD 20 DMA Support Bullish
2021-07-27 ISEE 1,2,3 Pullback Bullish Bullish Swing Setup
2021-07-27 ISEE 20 DMA Support Bullish
2021-07-27 ISEE Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-07-27 KALA New 52 Week Low Weakness
2021-07-27 KALA New 52 Week Closing Low Bearish
2021-07-27 KALA Hammer Candlestick Bullish
2021-07-27 KOD Pocket Pivot Bullish Swing Setup
2021-07-27 KOD 50 DMA Support Bullish
2021-07-27 MGTX Hammer Candlestick Bullish
2021-07-27 NGM Hammer Candlestick Bullish
2021-07-27 NGM Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-07-27 NGM Bollinger Band Squeeze Range Contraction
2021-07-27 NGM Fell Below 20 DMA Bearish
2021-07-27 NGM MACD Bearish Signal Line Cross Bearish
2021-07-27 OMER 20 DMA Resistance Bearish
2021-07-27 REGN Cup with Handle Other
2021-07-27 REGN 20 DMA Support Bullish
2021-07-27 RGNX Lower Bollinger Band Walk Weakness
2021-07-27 TCON Lower Bollinger Band Walk Weakness
2021-07-27 TCON Calm After Storm Range Contraction

Macular Degeneration Stocks Recent News

Date Stock Title
Jul 27 CLSD Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021
Jul 27 REGN ‘There’s a great opportunity that we’ll have another variant’: Doctor
Jul 27 GILD ‘There’s a great opportunity that we’ll have another variant’: Doctor
Jul 27 GILD Gilead (GILD) to Report Q2 Earnings: What's in the Cards?
Jul 27 GILD Prioritizing the Needs of the Black LGBTQ+ Community in an Innovative HIV Trial
Jul 27 REGN Regeneron, AstraZeneca to develop obesity treatment
Jul 27 REGN Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity
Jul 26 NGM Were Hedge Funds Right About NGM Biopharmaceuticals, Inc. (NGM)?
Jul 26 GILD Doctor on COVID-19 vaccination: ‘Too little too late, better late than never, if anything it all counts’
Jul 26 REGN Doctor on COVID-19 vaccination: ‘Too little too late, better late than never, if anything it all counts’
Jul 26 ISEE Iveric bio completes patient enrollment in Zimura eye disease trial
Jul 26 ISEE Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule
Jul 26 APLS Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
Jul 25 GILD The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Jul 23 GILD Doctor on the Olympics regarding COVID-19: ‘There are a lot of concerns’
Jul 23 REGN Doctor on the Olympics regarding COVID-19: ‘There are a lot of concerns’
Jul 23 NGM What Makes NGM Biopharmaceuticals (NGM) a New Buy Stock
Jul 23 ADVM Xenetic Biosciences, Medigus leads healthcare gainers; ImmunoPrecise Antibodies, Adverum Biotechnologies among major losers
Jul 23 ADVM Adverum plunges as analysts turn bearish citing setback for diabetic macular edema drug
Jul 23 KOD Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

More about Macular Degeneration
Browse All Tags